Emapticap pegol

BERLIN--( BUSINESS WIRE )-- TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces its plan to externalize and monetize the company's second clinical stage asset NOX-E36 – an L-stereoisomer RNA aptamer inhibiting the CCL2 chemokine. This decision leverages the compound’s potential, as shown by clinical and preclinical data, to safely address significant unmet medical needs in ophthalmic diseases impacted by fibrosis. The presence of the target of NOX-E36, CCL2, has been shown to predict early failure of glaucoma surgical intervention in patients and inhibition of the pathway targeted by NOX-E36 in preclinical models of glaucoma surgery prevents fibrosis thereby prolonging the success of the intervention 1 . NOX-E36 has already been administered to 175 clinical trial participants with an excellent safety and tolerability profile and showing activity on its target, already derisking a number of steps in early clinical development. Fibrosis is a significant cause of treatment failure or increased severity in many clinically important eye diseases 2 with unmet needs such as diabetic retinopathy (9.6 million cases in the US, of which 1.84 million vision-threatening 3 ), age-related macular degeneration (20 million cases in the US, of which 1.5 million vision-threatening 4 ), and primary open angle glaucoma (>3 million cases in the US 5 ). Click here to read the full press release 1 Chong (2017) Invest Ophthalmol Vis Sci 58:3432 & Chong (2010) Ophthalmology 117:2353 2 Sorenson (2024) Frontiers in Ophthalmology 2024 Vol. 4 3 Lundeen (2023) JAMA Ophthalmol. 2023;141(8):747-754 4 Rein (2022) JAMA Ophthalmol. 2022;140(12):1202-1208 5 US National Eye Institute Glaucoma Tables, Link

NOXXON Pharma N.V. announced that following discussions with investors it has received letters of intent and binding commitments for long-term investment of €1 million through a private placement plus additional commitment for a future private placement. Berlin, Germany, August 6, 2019, 08.00 p.m. CEST - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that following discussions with investors it has received letters of intent and binding commitments for long-term investment of €1 million through a private placement plus additional commitment for a future private placement. The price agreed with investors is €0.51 per share, representing a 10% discount on the average closing price of the shares over the seven trading days from July 24 to August 1, 2019. As such, it is anticipated that 1,960,780 new shares will be issued, provided that all letters of intent are fulfilled. Closing and settlement of this transaction is expected within the next 14 days. “We are greatly encouraged by the support of the investment community including our historical investors, Kreos and NGN, as well as more recent investors from German institutions and family offices. This investment allows us to continue to advance the Phase 1/2 brain cancer trial, which is one of the key clinical goals for NOXXON. The financing also brings in new, long-term investors committed to supporting our mission of developing innovative treatments for patients with difficult-totreat forms of cancer. There are no warrants or other option-like instruments attached to this financing,” said Aram Mangasarian, CEO of NOXXON. NOXXON is currently targeting the following upcoming milestones and corresponding financing measures: Additional equity by existing and new shareholders Upfront payments from licensing partnerships with biopharmaceutical company Co-financing of the brain cancer trial by an industrial partner Following-up on multiple M&A discussions “NOXXON is confident to close one or more of those options by the end of the first half of 2020. The results of our studies resonate positively with the pharmaceutical companies with which we are in conversation. This new round of funding additionally enables the company to move past the financing structures from the last years and unlock different financial options for a new chapter for NOXXON.” See the annex of this press release for further details on dilution related to this transaction. For more information, please contact: NOXXON Pharma N.V. Aram Mangasarian, Ph.D., Chief Executive Officer Tel. +49 (0) 30 726247 0 amangasarian@noxxon.com Trophic Communications Gretchen Schweitzer or Joanne Tudorica Tel. +49 (0) 89 2388 7730 or +49 (0) 176 2103 7191 schweitzer@trophic.eu NewCap Alexia Faure Tel. +33 (0) 1 44 71 98 51 afaure@newcap.fr About NOXXON NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the tumor microenvironment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, the lead program NOX-A12 has delivered top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients in December 2018 and further studies are being planned in these indications. The company initiated preparations for an additional trial with NOX-A12 in brain cancer in combination with radiotherapy. The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. The company’s second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors both as a monotherapy and in combination. Further information can be found at: Keytruda® is a registered trademark of Merck Sharp & Dohme Corp